Xcout IntelEton Pharmaceuticals, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Eton Pharmaceuticals, Inc. among pharmaceuticals companies — ranked by similarity to what Eton Pharmaceuticals, Inc. actually does, not by market-cap band.
Subscribe to see Eton Pharmaceuticals, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Eton Pharmaceuticals, Inc. at a glance
Eton Pharmaceuticals, Inc. is a pharmaceuticals company headquartered in Deer Park, United States. It is publicly listed (ETON) with a market capitalisation of $1.6B. Xcout tracks 14 named people at Eton Pharmaceuticals, Inc., including Sean E. Brynjelsen (President, Chief Executive Officer & Director).
Eton Pharmaceuticals, Inc. leadership
- Sean E. BrynjelsenPresident, Chief Executive Officer & Director
- Sean BrynjelsenChief Executive Officer & Director
- Danka RadosavljevicChief Operating Officer
- Judith MatthewsChief Financial Officer & Secretary
- Judy MatthewsChief Financial Officer
- David KrempaChief Business Officer
8 more named people on record for Eton Pharmaceuticals, Inc., with roles, board committees and tenure — see the full roster →
Eton Pharmaceuticals, Inc. funding rounds before its IPO
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $20.1M | — |
Financing after the IPO — public offerings and SEC Form D private placements — is not listed as a funding round.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Eton Pharmaceuticals, Inc. competitors
Ranked by semantic similarity — how close each company is to Eton Pharmaceuticals, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals company
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
Similar pharmaceuticals company
VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-weekly, long-acting growth hormone replacement designed for pediatric growth hormone deficiency. The company is also progressing other therapies, such as TransCon CNP (navepegritide), a long-acting prodrug utilizing c-type natriuretic peptide for achondroplasia, and Palopegteriparatide, a daily parathyroid hormone replacement therapy intended for chronic hypoparathyroidism. VISEN has forged strategic collaborations with Shanghai Pharmaceutical and United Family Healthcare. The enterprise was founded in 2018 and is based in Suzhou, China.
Similar pharmaceuticals company
Egetis Therapeutics is a specialty pharmaceutical company that develops and commercializes treatments for serious, rare diseases with high unmet medical need. Its lead product is Emcitate (tiratricol), a treatment for MCT8 deficiency. The company serves patients, caregivers, and healthcare professionals.
Biotechnology & Pharmaceuticals
ResQ Pharma, Inc. is a specialty pharmaceutical company founded in 2015 and headquartered in Glenview, Illinois, focused on providing reliable access to life-saving lipid-based therapies such as LipidRescue.
Similar pharmaceuticals company
Corcept Therapeutics Incorporated is a commercial-stage pharmaceutical company that develops and markets cortisol modulation therapies to treat serious medical conditions. The company focuses on modulating cortisol activity at the glucocorticoid receptor to create novel treatments across therapeutic areas such as endocrinology, oncology, metabolism, and neurology.
Similar pharmaceuticals company
Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on the development and commercialization of therapeutic products for rare and orphan diseases.
Similar pharmaceuticals company
Gen Pharmaceuticals (GEN İlaç) is a Turkish specialty pharmaceutical company established in 1998 and headquartered in Ankara, Turkey. The company manufactures and supplies products worldwide for rare diseases and unmet medical needs across therapeutic areas such as neurology, endocrinology, and nephrology.
Similar pharmaceuticals company
Ionis Pharmaceuticals, Inc. is a U.S.-based biotechnology company specializing in the discovery and development of RNA-targeted therapeutic agents. The company's commercialized portfolio features SPINRAZA, a treatment for spinal muscular atrophy (SMA) in both pediatric and adult patients. It also offers TEGSEDI, an injectable therapy for polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, and WAYLIVRA, approved for familial chylomicronemia syndrome and familial partial lipodystrophy. Beyond its marketed therapies, Ionis is actively progressing numerous drug candidates through pivotal Phase 3 clinical trials. These late-stage programs include Eplontersen, a monthly self-administered subcutaneous injection targeting all types of TTR amyloidosis; Olezarsen, designed for patients with severe hypertriglyceridemia (SHTG); Donidalorsen, for hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis; Pelacarsen, for individuals with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, developed to inhibit superoxide dismutase 1 production. Furthermore, Ionis is exploring treatments across a broader spectrum of therapeutic areas, such as metabolic, infectious, renal, ophthalmic diseases, and cancer. The company maintains a significant strategic collaboration with Biogen Inc. and holds various collaboration and licensing agreements with other prominent pharmaceutical partners, including AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Founded in 1989, Ionis Pharmaceuticals, Inc. operates from its headquarters in Carlsbad, California.
Similar pharmaceuticals company
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.
Similar pharmaceuticals company
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Similar pharmaceuticals company
Azurity Pharmaceuticals is a U.S.-based specialty pharmaceutical company that develops and commercializes medicines for underserved patient populations, including treatments for rare diseases and complex conditions. It focuses on patient-friendly dosage forms and serves healthcare providers, patients, and caregivers, including pediatric and other populations with unmet medication needs.
Similar pharmaceuticals company
Desitin Arzneimittel GmbH is a pharmaceutical company that develops and supplies medications for neurological and psychiatric conditions, including epilepsy, Parkinson's disease, and rare diseases. The company provides treatments and informational resources to patients, caregivers, and medical professionals.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Eton Pharmaceuticals, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Eton Pharmaceuticals, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →